Brief: Fortrea Holdings Will Continue To Work With Acelyrin To Complete Analysis Of The PSA Trial
29/11/2023 15:57
Nov 29 (Reuters) - Fortrea Holdings Inc FTRE.O :
* FORTREA HOLDINGS INC: WILL CONTINUE TO WORK WITH ACELYRIN
TO
COMPLETE THE ANALYSIS OF THE PSA TRIAL
* FORTREA HOLDINGS: CO "DISPUTES ACCURACY" OF STATEMENTS
THAT
ACELYRIN MADE IN PRESS RELEASE ON NOV 27
Source text for Eikon: ID:
Further company coverage: FTRE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fortrea Holdings
See all newsFortrea Q3 revenue beats expectations on bookings momentum, guidance raised
Brief: Fortrea And Omico Collaboration To Advance Biomarker-Led Oncology Drug Development
US RESEARCH ROUNDUP-Eli Lilly, Netflix, Zscaler
Brief: Fortrea Completes Acquisition Of The Early Phase Services Division From Worldwide Clinical Trials
US RESEARCH ROUNDUP-Acuity, Dell Technologies, Nike